Hindustan Times (East UP)

Panel to meet this week over Sputnik V approval

- Rhythma Kaul letters@hindustant­imes.com

NEW DELHI: The subject expert committee of the Central Drugs Standard Control Organisati­on (CDSCO) is likely to meet sometime this week to consider the emergency use applicatio­n of the Russian coronaviru­s vaccine Sputnik V, according to officials aware of the matter, who asked not to be named.

An approval to Sputnik V will add a third inoculatio­n to India’s arsenal of vaccines, which could be crucial in the fight against the pandemic at a time when the country is grappling with a resurgence in cases. The dose, made by the Gamaleya Research Institute, is 91.6% effective in preventing Covid-19, according to clinical trial findings.

“The committee looking into Covid related applicatio­n could convene any time this week,” said an official in the know of things. During the last meeting on the matter, the experts asked for safety and immunogeni­city data from Sputnik V’s phase II/III trials being conducted in India.

Sputnik V’s backers, the Russian Direct Investment Fund (RDIF), has tied up with five India-based pharma companies for production. The latest of these deals was announced on Monday. Virchow Biotech will produce 200 million doses, the RDIF announced.

“Vaccine partnershi­ps are the only way to overcome the pandemic. The world continues its fight against coronaviru­s and we see a growing interest in Sputnik V vaccine as it is one of the most efficient vaccines available. The agreement with Virchow Biotech is an important step to facilitate the fullscale local production of the vaccine in India and to supply our internatio­nal partners globally,” said Kirill Dmitriev, chief executive officer f the Russian Direct Investment Fund (RDIF). Virchow indicated the production is likely to be for “internatio­nal partners” of RDIF.

Tummuru Murali, managing director of Virchow Biotech, said, “We are glad to sign a cooperatio­n agreement with RDIF to produce the Sputnik V coronaviru­s vaccine. Virchow’s proven capabiliti­es in large scale drug substance manufactur­ing should help meet the global demand for this vaccine...”

The cumulative number of Covid-19 vaccine doses administer­ed in the country has crossed 47,207,134 with 1,965,635 doses being given on Monday, the Union Health Ministry said in a statement on Monday.

These include over 7.8 million Health Care Workers who have taken the first dose and over 4.9 million Health Care workers who have taken the 2nd dose, over 8.1 million frontline workers who have taken the first dose and around 2.8 million frontline workers who have taken 2nd dose, according to the press release.

Newspapers in English

Newspapers from India